Genascence Receives $11.6 Million Award From California Institute for Regenerative Medicine to Help Advance its Lead Gene Therapy Program in Knee Osteoarthritis

Genascence Corporation announced it has been awarded $11.6 million over four years from the California Institute for Regenerative Medicine . The funding will be used to support Genascence’s Phase 1b clinical trial of GNSC-001 in knee osteoarthritis, as well as phase-appropriate manufacturing activities.